NovelWise partners with QuantHealth on AI oncology development

NovelWise said Tuesday it is working with QuantHealth to add AI-driven clinical trial simulations to its oncology development planning. The collaboration is meant to help the clinical-stage biotech evaluate options, use research resources more efficiently and strengthen evidence-based decisions.

Why it matters: - NovelWise is adding AI-enabled trial simulation to its oncology development workflow. - The collaboration is meant to support evidence-informed decisions in a field where trial design, timing and resource allocation can shape whether programs move forward. - NovelWise framed the deal as part of a broader strategy to combine internal science with outside technology and expertise.

What happened: - NovelWise Pharmaceutical Corporation USA announced a collaboration with QuantHealth on Tuesday, Sept. 23, 2026. - NovelWise is a clinical-stage biotechnology company developing novel oncology therapeutics. - QuantHealth is an AI-driven clinical trial simulation company. - The engagement gives NovelWise access to QuantHealth’s computational capabilities for clinical development planning. - The collaboration is intended to add an analytical perspective to NovelWise’s scientific and clinical expertise.

The details: - NovelWise plans to use the AI tools to evaluate development options and support more disciplined use of research resources. - CY Huang, chairman of NovelWise Pharmaceutical Corporation, said the company sees AI as a way to challenge assumptions, explore alternatives and strengthen the evidence behind development strategy. - NovelWise said its model combines proprietary therapeutic development with specialized external technologies and expertise. - AI-generated insights will be weighed alongside available scientific evidence and expert judgment. - The company said the insights are meant to support development decisions, not replace clinical trials. - NovelWise said the collaboration does not establish the safety or efficacy of any investigational therapy. - More information is available on NovelWise’s website. - More information is available on QuantHealth’s website.

Between the lines: - The deal signals how biotech companies are increasingly using simulation tools earlier in development to pressure-test decisions before expensive trials. - NovelWise is also signaling that AI will be used as a decision-support layer, not as a substitute for clinical evidence. - QuantHealth’s pitch is centered on using real-world data and predictive modeling to simulate trials, optimize protocols, reduce risk and speed timelines. - QuantHealth said it has run more than 600 trial simulations across 30 diseases and works with 12 of the top 20 global pharmaceutical companies.

What's next: - NovelWise will incorporate QuantHealth’s AI-generated insights into future clinical development planning. - Any effect on specific oncology programs will depend on scientific, technical, clinical and regulatory outcomes. - The company said the collaboration does not guarantee favorable findings, successful development or regulatory approval.

The bottom line: - NovelWise is betting that AI trial simulation can sharpen oncology development decisions without replacing the need for traditional clinical trials.